Here, we describe a comprehensive clinical testing approach for the assessment of the BRCA1/2 genes in ovarian cancer specimens, which can be used to determine patients’ eligibility for PARP inhibitor therapy. The gene discussed is BRCA1; the disease is ovarian carcinoma.